Navigation Links
AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
Date:6/8/2009

risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements, and we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested to do so by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
2. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
3. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
4. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
5. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
6. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
7. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
8. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
9. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
10. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... (OTCBB:GNBT) today announced that it has entered into ... to which UHN,s Centre for Molecular Design and ... refinement project.  The goal of the project is ... the Company,s proprietary buccal insulin spray product, thereby ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
(Date:9/22/2014)... The US markets on Friday, ... the Dow Jones Industrial Average finished at 17,279.74, up ... 0.30%. The S&P 500 finished the session 0.05% lower ... ten sectors finished on a positive note. The S&P ... 751.48, up 0.10%, with the index gaining 6.95% in ...
(Date:9/22/2014)... , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic products ... Robert Bazemore as Chief Operating Officer.  ... President and Chief Executive Officer, Robert will oversee ... lead program, sebelipase alfa for LAL Deficiency, and ...
Breaking Biology Technology:Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... interesting meeting took place this past week at the University ... The focus of the meeting was an opportunity to hear ... last annual BIO meetings in different cities, as a preview ... this Olympics of Biotechnology meeting comes to Chicago in April, ...
... hit a nerve. , , I heard from a number ... 2.0 is spelled b-u-b-b-l-e, and who want none of it. As ... use a healthy dose of caution to prevent the heavy Kool-Aid ... group. , ,Indeed, in dozens of conversations with start-ups seeking a ...
... and after its recent redesign The Internal Revenue Service ... well as tweaking its search engine to hopefully make it easier ... keeping roughly the same design since mid-2002, the IRS decided to ... Among other features, the site has links to the most-requested publications ...
Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6Can we prevent Web 2.0 from being a bubble? 2Can we prevent Web 2.0 from being a bubble? 3
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... significantly less likely to report taking iron supplements before ... who are developing normally, a study by researchers with ... iron intake was associated with a five-fold greater risk ... 35 or older at the time of the child,s ... as obesity hypertension or diabetes. , The research is ...
(Date:9/21/2014)... at the University of California, San Diego, have developed ... that control the activity of genes based on sequences ... from its application to human embryonic cells in a ... 21. , "All of our cells have the same ... said John Whitaker, lead author of the report. "Skin ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
... Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the ... approved,the scheme of arrangement between Shire plc and ... which becomes effective on 23 May 2008,results in ... SHP,NASDAQ: SHPGY) becoming the new holding company for ...
... CORVALLIS, Ore. An international team of scientists surveying ... Coast of North America has discovered for the first ... miles of the shoreline, raising concern for marine ecosystems ... an Oregon State University research vessel, also discovered that ...
... called FIGLA cause premature ovarian failure in at least a ... from Baylor College of Medicine in Houston and Shandong University ... the American Journal of Human Genetics. We hope to ... genes associated with this problem to find biomarkers in blood ...
Cached Biology News:Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3Oocyte-specific gene mutations cause premature ovarian failure 2
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Biology Products: